Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Beam Therapeutics Appoints Christi Shaw to its Board of Directors
Beam Therapeutics Reports Third Quarter 2023 Financial Results
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
Beam Therapeutics is selling opt-in rights to Verve’s gene therapy programs aimed at cardiovascular disease to Eli Lilly for up to $600 million, a third of which is upfront cash.
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-301, to directly correct the R83C mutation, one of the primary disease-causing mutations of glycogen storage disease type Ia (GSDIa). The data were presented today in an oral presentation titled “A Single, Systemic Administration of BEAM-301 Mitigated Fasting Hypoglycemia One Year after Dosing in a Transgenic Mouse Model of Glycogen Storage Disease Type-Ia” at the 30th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in Brussels.
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced portfolio priorities and plans to streamline its business operations to support potential near-term value drivers and long-term growth. This plan includes cost reduction initiatives that align with the company’s near-term goals, and the anticipated cost savings are expected to extend its revised operating plan into 2026.